Replies to post #263735 on Avid Bioservices Inc (CDMO)

[biopharm]

May 10, 2016

Phosphatidylserine exposure is required for ADAM17 sheddase function

http://www.nature.com/ncomms/2016/160510/ncomms11523/abs/ncomms11523.html#affil-auth

It seems that Adam17 with direct links to exposure of flipped PS...and iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling

http://www.pubfacts.com/author/Thorsten+Maretzky

https://www.researchgate.net/publication/276462016_iRhoms_1_and_2_are_essential_upstream_regulators_of_ADAM17-dependent_EGFR_signaling

------------------

Now we know many oncologists require / advise testing for EGFR mutation and I'd say PS Targeting is closer than we think if news continues

http://www.questdiagnostics.com/testcenter/testguide.action%3Fdc%3DTS_LungCancerMutation_Panel

------------------

Recommendation

In the provisional clinical opinion, ASCO recommends that if a doctor is thinking about giving an EGFR TKI to a patient with advanced non-small cell lung cancer who has not previously had chemotherapy or an EGFR TKI, the doctor should test the tumor EGFR mutations to determine the most appropriate treatment. Testing for EGFR is done on the sample of tumor removed during a biopsy.

http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/epidermal-growth-factor-receptor-egfr-testing-advanced-non-small-cell-lung-cancer

--------------------

I think AstraZeneca already knows Durvalumab would work out best with PS Targeting.... instead of AZ's Gefitinib

Lets go Peregrine.....what does the next little round of news include